FORM 4

Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHANGES IN BENEFICIAL	OWNERSHIP
obligations may continue. See		

OMB APPRO	OVAL				
OMB Number:	3235-0287				
Estimated average burd	en				
hours per response:	0.5				

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Desjardins Clarissa</u>					2. Issuer Name and Ticker or Trading Symbol Xenon Pharmaceuticals Inc. [XENE]						(Ch	elationship of the contract of	,		on(s) to Issu 10% Ow	
(Last) (First) (Middle) 200 - 6350 GILMORE WAY					3. Date of Earliest Transaction (Month/Day/Year) 01/13/2020							Officer below)	(give title		Other (s below)	pecify
(Street) BURNA (City)		tate)	V5G 4W8	_	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	ndividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person				1	
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transa Date (Month/D			ansaction	ction 2A. Deemed Execution Date,		3. Transaction	4. Securi Disposed tr. 5)	urities Acquired (A) of (D) (Instr. 3, 4		5. Amount of 6 Securities F Beneficially (I		Form:	Direct of Indirect str. 4)	7. Nature of Indirect Beneficial Ownership Instr. 4)		
		7	Table II - Deri (e.g.					uired, Dis , options,				Owned			<u> </u>	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		5. Number of (Instr. Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Ownershi Form: Direct (D) or Indirect (I) (Instr. 4	Ownership Form:	Beneficial Ownership (Instr. 4)				
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$16.42	01/13/2020		A		25,000		(1)	01/12/2030	Common Shares	25,000	\$0.00	25,000)	D	

Explanation of Responses:

1. One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date.

Remarks:

/s/ Cassandra Robinson, 01/14/2020 Attorney-in-fact

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.